Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Free Cash Flow (2023 - 2026)

Camp4 Therapeutics' Free Cash Flow history spans 3 years, with the latest figure at $6.2 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 156.23% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$29.8 million, a 34.52% increase, with the full-year FY2025 number at -$29.8 million, up 34.52% from a year prior.
  • Free Cash Flow hit $6.2 million in Q4 2025 for Camp4 Therapeutics, up from -$11.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CAMP hit a ceiling of $6.2 million in Q4 2025 and a floor of -$14.3 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$9.7 million across 3 years, with a median of -$11.2 million in 2024.
  • The widest YoY moves for Free Cash Flow: up 156.23% in 2025, down 28.03% in 2025.
  • Tracing CAMP's Free Cash Flow over 3 years: stood at -$12.0 million in 2023, then increased by 7.62% to -$11.1 million in 2024, then skyrocketed by 156.23% to $6.2 million in 2025.
  • Business Quant data shows Free Cash Flow for CAMP at $6.2 million in Q4 2025, -$11.2 million in Q3 2025, and -$10.6 million in Q2 2025.